Another look at the human papillomavirus vaccine experience in Canada
- PMID: 21852642
- PMCID: PMC3222351
- DOI: 10.2105/AJPH.2011.300205
Another look at the human papillomavirus vaccine experience in Canada
Abstract
Policy debates about immunization frequently focus on classic trade-offs between individual versus collective well-being. Publicly funded immunization programs are usually justified on the basis of widespread public benefit with minimal individual risk. We discuss the example of the policy process surrounding the adoption of the human papillomavirus (HPV) vaccine in Canada to consider whether public good arguments continue to dominate immunization policymaking. Specifically, we show how a range of stakeholders framed HPV vaccination as a personal-rather than a public-matter, despite the absence of a controversy over mandatory immunization as was the case in the United States. Our findings suggest an erosion of the persuasiveness of public good arguments around collective immunization programs in the policy discourse.
References
-
- Healthy People 2010: Understanding and Improving Health. Washington, DC: US Department of Health and Human Services; 2000. Also available at: http://web.health.gov/healthypeople/document. Accessed May 12, 2011
-
- Gauri V, Khaleghian P. Immunization in Developing Countries: Its Political and Organizational Determinants. Washington, DC: World Bank; 2002. World Bank Policy Research Working Paper 2769
-
- National Advisory Committee on Immunization Statement on human papillomavirus vaccine. Canada Communicable Disease Report. 2007;33(ACS-2):1–32 - PubMed
-
- Dawar M, Dobson S, Deeks S. Literature Review on HPV 6, 11, 16 and 18: Disease and Characteristics. Review commissioned by the Public Health Agency of Canada; Ottawa, Canada: Public Health Agency of Canada; 2007. Available at: http://www.atlantique.phac.gc.ca/naci-ccni/pdf/lr-sl_2_e.pdf. Accessed July 12, 2010
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
